Synonyms: MK7762 | TBD09
Compound class:
Synthetic organic
Comment: MK-7762 (also known as TBD09) is the oxazolidinone antibacterial compound claimed in Merck's patent WO2021188606A1 [1]. It is being developed as a treatment for tuberculosis (TB) by Merck and the Bill & Melinda Gates Medical Research Institute.
|
|
Bioactivity Comments |
MK-7762 inhibits 95% of the growth of Mycobacterium tuberculosis at a concentration of 0.71-1.16 μM in vitro [1]. |